2.Clinical and Laboratory Features of Korean Mucopolysaccharidoses (MPSs) .
Woo Yun SOHN ; Jee Hyun LEE ; Kyung Hoon PAIK ; Eun Kyoung KWON ; Ahn Hee KIM ; Dong Kyu JIN
Korean Journal of Pediatrics 2005;48(10):1132-1138
PURPOSE: The mucopolysaccharidoses (MPSs) are a heterogeneous group of lysosomal storage disorders. They are caused by a deficiency of the enzymes involved in the degradation of glycosaminoglycans. Early recognition is important because recombinant enzyme replacement therapy is now available for MPS. We studied the clinical characteristics of 80 MPS children with the object of determining the epidemiological, clinical and radiological features in Korean MPS children. METHODS: Diagnosis of MPS was confirmed by skin fibroblast enzyme analysis in 80 patients between February 1995 and December 2004. Charts were retrospectively reviewed for clinical and radiological findings, as well as for intelligence and speech evaluations. RESULTS: Hunter syndrome (MPS type II) was the most prevalent type, appearing in 51/80 cases (64 %), followed by Sanfilippo syndrome (MPS III-18%), Hurler syndrome (MPS I-15%), and Morquio syndrome (MPS IV-4%). The average age at diagnosis was 5.5 years (range 1 to 20), and the male-to-female ratio was 4.7: 1. Typical radiographic changes were observed in 45/54 cases (83%). Mitral regurgitation was the most common cardiac defect. Moderate to profound mental retardation and hearing loss were present in 14/35 cases (56%) and 33/38 cases (82%), respectively. Four MPS II patients had bone marrow transplantation, with mixed outcomes. Five MPS I patients are currently on enzyme replacement therapy. CONCLUSION: Our study showed a high proportion of MPS II cases (64%), which may represent population variability. By studying the clinical features of these patients, we hope to alert pediatricians of the warning signs of MPS.
Bone Marrow Transplantation
;
Child
;
Diagnosis
;
Enzyme Replacement Therapy
;
Fibroblasts
;
Glycosaminoglycans
;
Hearing Loss
;
Hope
;
Humans
;
Incidence
;
Intellectual Disability
;
Intelligence
;
Korea
;
Mitral Valve Insufficiency
;
Mucopolysaccharidoses*
;
Mucopolysaccharidosis I
;
Mucopolysaccharidosis II
;
Mucopolysaccharidosis III
;
Mucopolysaccharidosis IV
;
Retrospective Studies
;
Skin
3.Allogeneic hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis type 1: a case report.
Rui-Ming OU ; Ling WANG ; Li-Ling ZHENG ; Meng-Dong YAO ; Wei-Tao JIANG ; Chang-Hua ZHOU
Chinese Journal of Contemporary Pediatrics 2006;8(3):181-183
Mucopolysaccharidosis type I (MPS-I) is an inborn error of metabolism with progressive multisystem involvement. Hurler syndrome is the most severe form of MPS-I that causes progressive deterioration of the central nervous system with ensuing death. This study reported the therapeutic effect of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on Hurler syndrome in one case. The patient was a 25-month-old boy. He underwent allo-HSCT. The donor was his elder sister whose HLA-B locus was not matching. The reduced-intensity of BuCy conditioning regimen in allo-HSCT for this patient was as follows: busulfan 3.7 mg/kg daily at 9 to 6 days before transplantation, cyclophosphamide 42.8 mg/kg daily at 5 to 2 days before transplantation, and rabbit antithymocyte globulin 3.5 mg/kg daily at 1, 3, 5, and 7 days before transplantation. Human granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells (CD34+ cells 12.8 x10(6)/kg) were infused and cyclosporine (CSA), short-course methotrexate, daclizumab and mycophenolate mofetil (MMF) were administered to prevent graft-versus-host disease (GVHD). Complete donor-type engraftment was confirmed by Short Tandem Repeat-Polymerase Chain Reaction (STR-PCR) on day 14 after transplantation. Neutrophil and platelet engraftment occurred on days 11 and 19 after transplantation respectively. Only grade I regimen-related toxicity of live and gastrointestinal tract occurred. GVHD and graft failure were not observed. After transplantation, the clinical symptoms and the neurocognitive function were greatly improved in this patient. It was concluded that allo-HSCT was effective for the treatment of MPS-I. The reduced-intensity conditioning regimen was helpful to decrease the regimen-related toxicity. Sufficient immunosuppressive therapy and adequate hematopoietic stem cells infusion may be beneficial to the donor cell engraftment and reducing the incidence of graft failure and GVHD.
Child, Preschool
;
Follow-Up Studies
;
Graft vs Host Disease
;
etiology
;
Hematopoietic Stem Cell Transplantation
;
Humans
;
Male
;
Mucopolysaccharidosis I
;
therapy
;
Transplantation, Homologous